Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Stil

Summary

Gary Black calls Eli Lilly's valuation 'compelling' as Q1 earnings soar, driven by the consumer 'love affair' with GLP-1 weight loss drugs.

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage